EAM
ADMA icon

Evanson Asset Management’s ADMA Biologics ADMA Stock Holding History

Evanson Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$29K – 247
2020
Q2 		$29K Hold
10,000
– – 0.01% 230
2020
Q1 		$29K Buy
+10,000
New +$34.6K 0.01% 215

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evanson Asset Management's ADMA Position: Q3 2020 in Review

Evanson Asset Management sold out of ADMA Biologics (ADMA) in Q3 2020, closing a stake of 10,000 shares — an estimated $29K sold.

Evanson Asset Management first reported a position in ADMA in Q1 2020 and held it in 2 quarters. The position peaked at $29K in Q2 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q3 2020.

  • Evanson Asset Management reported no remaining ADMA Biologics position as of Q3 2020 after selling out during the quarter.
  • Evanson Asset Management sold 10,000 ADMA Biologics shares in Q3 2020, an estimated $29K.
  • Evanson Asset Management first reported a position in ADMA Biologics in Q1 2020 and held it in 2 quarters.
  • Evanson Asset Management's ADMA Biologics position peaked at $29K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2020.

Based on Evanson Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.